Skip to content
Screener

Retained Earnings at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$60.63B+11.4%
Danaher logo
DanaherDHR
$48.23B+6.6%
Azenta logo
AzentaAZTA
$1.25B
Agilent Technologies logo
Agilent TechnologiesA
$1.69B+85.5%
Illumina logo
IlluminaILMN
-$258M+76.8%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$128.07M-450%

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$6.84B+338%
Enterprise value$6.83B+370%
P/S16.7×+12.4×

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0001581280-26-000040
(In thousands, except per share data)March 31,2026September 30,2025
Commitments and contingencies (Note 11)
Stockholders’ equity
Common stock, $0.00001 par value —200,000 and 200,000 shares authorized at March 31, 2026 and September 30, 2025, respectively; 62,154 and 60,632 shares issued and outstanding at March 31, 2026 and September 30, 2025, respectively$1
Additional paid-in capital1,849,8381,793,163
Accumulated other comprehensive loss(639)(627)
Accumulated deficit(1,394,106)(1,319,578)
Total stockholders’ equity$455,094$472,958
Total liabilities and stockholders’ equity$676,214$641,861

Item 1. Financial Statements (unaudited)

FAQ

What is Twist Bioscience Corporation's retained earnings?
Twist Bioscience Corporation (TWST) reported retained earnings of -$1.39B in Q1 2026.
How has Twist Bioscience Corporation's retained earnings changed year-over-year?
Twist Bioscience Corporation's retained earnings decreased by 6.2% year-over-year, from -$1.31B to -$1.39B.
What is the long-term trend for Twist Bioscience Corporation's retained earnings?
Over 4 years (2021 to 2025), Twist Bioscience Corporation's retained earnings has grown at a 21.2% compound annual growth rate (CAGR), from -$610.55M to -$1.32B.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Twist Bioscience Corporation's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude